OpenClinica Announces Mobile Participant Solution
Participate sets a new standard for usability, integration, and cost effectiveness for electronic patient reported outcomes (ePRO).
OpenClinica announced Participate, a mobile, device-independent solution for engaging participants in clinical research. Participate broadens possibilities for clinical research, by making it easier to meaningfully engage patients and collect high quality, timely data from patients in a way that is convenient for them.
To date, OpenClinica has been known for its clinical trial electronic data capture software. The addition of Participate adds a friendly and effective way to engage patients directly in those same OpenClinica-powered clinical studies. Using Participate with OpenClinica EDC allows researchers to design participant-facing events, reminders, and assessments alongside clinical visits and CRFs, using OpenClinica's existing study build tools. All the clinical and patient reported outcomes data are captured in a single place. As data are submitted by study participants, their activities become part of the same regulatory compliant audit trail that tracks all clinical user activity. The data participants submit, are immediately available for review and analysis alongside CRF data from other sources.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
